Fossberg E, Beisland H O, Lundgren R A
Urol Int. 1983;38(5):293-9. doi: 10.1159/000280909.
23 females, mean age 53 years, with genuine stress incontinence were treated with phenylpropanolamine (PPA), 50 mg twice daily, versus placebo. Simultaneous urethrocystometry with recording of the transmission of increased abdominal pressure to the bladder and the urethra was carried out, and serum concentration of PPA measured and related to subjective effect, effect on the maximal urethral closure pressure (MUCP) and on the pressure transmission ratio. 3 patients were excluded, 1 because of side effects, and 2 were dropouts. 12 patients reported improvement while on PPA, but none became continent. 3 patients improved on placebo. The remaining patients were unchanged. A plasma level of PPA of more than 150 ng/ml seemed necessary to obtain an effect; this level was reached after approximately 90 min after intake of 50 mg. Objectively a rise in MUCP was recorded, but there was no correlation between serum concentration and the increase in MUCP. An improvement of the pressure transmission ratio was also recorded.
23名平均年龄53岁的真性压力性尿失禁女性接受了苯丙醇胺（PPA）治疗，每日两次，每次50毫克，与安慰剂进行对比。同时进行尿道膀胱测压，记录增加的腹压向膀胱和尿道的传导情况，并测量PPA的血清浓度，并将其与主观效果、对最大尿道闭合压（MUCP）的影响以及压力传导率相关联。3名患者被排除，1名因副作用，2名是退出者。12名患者在服用PPA时报告有改善，但无人实现控尿。3名患者在服用安慰剂时有所改善。其余患者无变化。似乎需要PPA血浆水平超过150纳克/毫升才能获得效果；摄入50毫克后约90分钟达到该水平。客观上记录到MUCP升高，但血清浓度与MUCP升高之间无相关性。还记录到压力传导率有所改善。
